MedTrace Logo

Utility of PCD Diagnostics to Improve Clinical Care

NCT05889013 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-09-22

No results posted yet for this study

Summary

This cross-sectional and longitudinal observational study is to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). There is new testing available, called nasal nitric oxide testing, that non-invasively measures nitric oxide levels in the sinus cavity. Individuals with PCD characteristically have low levels, but this testing does not have extensive data from everyday clinical practice. The objective of this proposal is to improve the diagnostic approach to children and adults with clinical concerns for primary ciliary dyskinesia (PCD).

Conditions

  • Primary Ciliary Dyskinesia

Interventions

DEVICE

Nasal Nitric Oxide testing

Collection of already performed clinical data and nNO testing

Sponsors & Collaborators

  • UConn Health

    collaborator OTHER

  • Connecticut Children's Medical Center

    lead OTHER

Principal Investigators

  • Melanie S Collins, MD · Connecticut Children's Medical Center

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-17
Primary Completion
2027-12-31
Completion
2028-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05889013 on ClinicalTrials.gov